Opinion|Videos|August 7, 2024
AYA ALL: Pediatric and Adult Inspired Regimens
Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.
Advertisement
Video content above is prompted by the following questions:
- What is the current treatment landscape for AYA ALL?
- How has the treatment landscape evolved over time?
- What is the role of asparaginase in the treatment of ALL in adolescents and young adults (AYA)?
- What are some challenges in treating this patient population?
- When treating AYA ALL in your practice, do you usually consider a pediatric-inspired regimen or an adult-inspired regimen?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
4
The OncFive: Top Oncology Articles for the Week of 8/16
5